AnaptysBio, which filed for the IPO in 2015, has gone public in an offering that will give long-term investor Novo an exit.
Pharmaceutical company Novo has exited AnaptysBio, a US-based developer of inflammation and immuno-oncology treatments, through a $75m initial public offering on Nasdaq.
AnaptysBio floated yesterday after pricing 5 million shares at $15 each. Undisclosed existing investors have agreed to buy a further 1.95 million shares at the IPO price but the company has not revealed their identity or the details of their plans.
Founded in 2005, AnaptysBio is developing antibody-based drugs that will treat severe inflammatory disorders. It initially…
